Abstract
Objective: The aim of this study was to study the effect of intravitreal anti-vascular endothelial growth factor (VEGF) on the visual acuity (VA) using logMAR charts and the contrast sensitivity (CS) using the pelli-robson chart in patients of advanced diabetic retinopathy.
Design: We performed a retrospective study to assess the change in CS and VA in diabetic retinopathy (DR) with or without proliferative DR patients receiving intra-vitreal anti VEGF.
Methods: The study was done at our institution where 40 patients of DR were included in the study, 20 cases (20 eyes) and 20 controls (20 eyes). Moreover, it comes under the criteria of low vision and above 18 years of age and VA >6/60. VA and CS were compared before injection and after injection at 14 days, 30 days, and 90 days, respectively.
Results: On comparing the mean of CS change before injections and after injections at 14 days (p=0.036), 30 days (p=0.012), and 90 days (p=0.012), respectively, showed a significant association between change in CS change within group but on comparing with control group at 14 days (p=0.195), 30 days (p=0.247), 90 days (p=0.247), respectively, showed no significant association. Another comparison of mean VA before injection and after injection in the case group at 14 days, 30 days, and 90 days, respectively, (p=0.329) remains the same. Which is insignificant but on comparison with the control group (p=0.02) showed a significant association.
Conclusion: Whatever VA and CS are achieved with anti-VEGF was completed at 14 days of injection.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference13 articles.
1. Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers 2016;2:16012. doi: 10.1038/ nrdp.2016.12, PMID 27159554
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519
3. Prevention of blindness from diabetic retinopathy. Report of a WHO consultation. Geneva: WHO; 2005.
4. Guidelines for the Comprehensive Management of Diabetic Retinopathy in India. A Vision 2020 the Right to Sight India Publication; 2008.
5. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, MossSE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63. doi: 10.1001/ archopht.122.4.552, PMID 15078674